Back to Pipeline

Tebotelimab (PD-1xLAG-3)

Overview

Tebotelimab (MGD013) is a bispecific monoclonal antibody. It is anticipated that MGD013 could be used for the treatment of a wide range of cancers, including both solid tumors and hematological malignancies. A Phase I dose escalation study of MGD013 is ongoing.  In November 2018, Zai Lab obtained regional development and commercialization rights of MGD013 in mainland China, Hong Kong (China), Macau (China) and Taiwan region from MacroGenics Inc.